EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC-ND 4.0

Chimeric antigen receptor (CAR) T-cell therapy: Harnessing extracellular vesicles for enhanced efficacy

Beatrice Spokeviciute, Sharad Kholia, Maria Felice Brizzi

Pharmacological Research · 2024

DOI: 10.1016/j.phrs.2024.107352 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Pharmacological Research, 2024. Verfasst von Beatrice Spokeviciute und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Sciences, University of Torino, Turin, Italy. Hauptthemen laut MEDLINE: Extracellular Vesicles, Receptors, Chimeric Antigen, Immunotherapy, Adoptive, Neoplasms. Die Arbeit wurde bisher 20-mal zitiert (Crossref) und nennt 175 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

A cutting-edge approach in cell-based immunotherapy for combating resistant cancer involves genetically engineered chimeric antigen receptor T (CAR-T) lymphocytes. In recent years, these therapies have demonstrated effectiveness, leading to their commercialization and clinical application against certain types of cancer. However, CAR-T therapy faces limitations, such as the immunosuppressive tumour microenvironment (TME) that can render CAR-T cells ineffective, and the adverse side effects of the therapy, including cytokine release syndrome (CRS). Extracellular vesicles (EVs) are a diverse group of membrane-bound particles released into the extracellular environment by virtually all cell types. They are essential for intercellular communication, transferring cargoes such as proteins, lipids, various types of RNAs, and DNA fragments to target cells, traversing biological barriers both locally and systemically. EVs play roles in numerous physiological processes, with those from both immune and non-immune cells capable of modulating the immune system through activation or suppression. Leveraging this capability of EVs to enhance CAR-T cell therapy could represent a significant advancement in overcoming its current limitations. This review examines the current landscape of CAR-T cell immunotherapy and explores the potential role of EVs in augmenting its therapeutic efficacy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Extracellular VesiclesReceptors, Chimeric AntigenImmunotherapy, AdoptiveNeoplasmsHumansAnimalsTumor MicroenvironmentT-LymphocytesReceptors, Antigen, T-Cell

Stichwörter der Autor:innen

(CAR) T-cell therapyCancerExtracellular vesiclesImmune modulationTumour microenvironment

Substanzen

Receptors, Chimeric AntigenReceptors, Antigen, T-Cell

Autor:innen und Institutionen

  • Department of Medical Sciences, University of Torino, Turin, Italy.
  • Department of Medical Sciences, University of Torino, Turin, Italy. Electronic address: mariafelice.brizzi@unito.it.

Zitieren

APA

Spokeviciute, B., Kholia, S., & Brizzi, M. F. (2024). Chimeric antigen receptor (CAR) T-cell therapy: Harnessing extracellular vesicles for enhanced efficacy. Pharmacological Research. https://doi.org/10.1016/j.phrs.2024.107352

Vancouver

Spokeviciute B, Kholia S, Brizzi MF. Chimeric antigen receptor (CAR) T-cell therapy: Harnessing extracellular vesicles for enhanced efficacy. Pharmacological Research. 2024. doi:10.1016/j.phrs.2024.107352

BibTeX
@article{Spokeviciute2024,
  author = {Spokeviciute, Beatrice and Kholia, Sharad and Brizzi, Maria Felice},
  title = {Chimeric antigen receptor (CAR) T-cell therapy: Harnessing extracellular vesicles for enhanced efficacy},
  journal = {Pharmacological Research},
  year = {2024},
  doi = {10.1016/j.phrs.2024.107352}
}
Kostenlos starten →